8-K: Vaxart Terminates At-the-Market Offering Agreement, Concluding $28.6 Million in Share Sales

Vaxart has terminated its Controlled Equity Offering Sales Agreement, effective October 18, 2024, after selling 17.5 million shares for $28.6 million since September 2021.

Summary

• Vaxart, Inc. has terminated its Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc., effective October 18, 2024.
• The Sales Agreement allowed Vaxart to sell shares of common stock in an at-the-market offering.
• From September 15, 2021, to October 8, 2024, Vaxart sold 17,501,561 shares of common stock.
• The total gross proceeds from these sales amounted to approximately $28.6 million.
• Vaxart will not incur any penalties for terminating the Sales Agreement.
• The company does not plan to sell any additional shares under this agreement before its termination.

Sentiment

Score: 6

Explanation: The document is neutral, reporting the termination of an agreement after the planned share sales were completed. There are no indications of financial distress or significant positive developments.

Positives

• Vaxart successfully raised $28.6 million through the at-the-market offering.
• The termination of the agreement does not incur any penalties for the company.
• The company has completed its planned share sales under this agreement.

Negatives

• The termination of the Sales Agreement means Vaxart can no longer use this method to raise capital.
• The company has not disclosed any alternative funding plans.

Risks

• The termination of the Sales Agreement may limit Vaxart's immediate access to capital through at-the-market offerings.
• The company may need to explore alternative financing options in the future.

Future Outlook

The company does not intend to issue or sell any additional shares of common stock under the Sales Agreement prior to its termination.

Management Comments

• The company provided notice to the Sales Agents to terminate the Sales Agreement.

Industry Context

At-the-market offerings are a common method for biotech companies to raise capital, and the termination of such an agreement is not unusual when a company's funding needs or market conditions change.

Comparison to Industry Standards

• Many biotech companies, such as Novavax and Moderna, have utilized at-the-market offerings to raise capital.
• The amount raised by Vaxart, $28.6 million, is relatively small compared to some larger biotech companies, but is typical for a company of its size and stage of development.
• The termination of the agreement is not unusual and is often a strategic decision based on market conditions and the company's financial needs.

Stakeholder Impact

• Shareholders may be impacted by the termination of the at-the-market offering, as it removes a potential source of funding for the company.
• The company's ability to raise capital in the future may be affected.

Key Dates

Keywords

Vaxart, equity offering, share sales, capital raise, at-the-market, Cantor Fitzgerald, B. Riley Securities, financing